Adverse Outcomes Associated With Off-Label Agents Used to Treat Dementia Patients With Psychosis: A Case-Control Medicare Database Study.
Nazia RashidJames B WetmoreMuna IrfanVictor AblerPublished in: American journal of Alzheimer's disease and other dementias (2022)
Current agents used for DRP were associated with increased risk of death and adverse outcomes. An increased risk of death was evident within 3 months of antipsychotic/divalproex initiation and persisted with long-term use.